If you have a spare $2,500 and want to invest it wisely, these four ASX shares are tipped to multiply your investment.
Image source: Getty Images
Nextdc Ltd (ASX: NXT)
Nextdc operates a fast-expanding network of data centres for cloud computing and telecommunications, and it also supports AI workloads. It has physical centres, cooling, power, security services, and also project support. I think that, as data usage grows, demand for this type of secure, high-quality infrastructure will also increase. Some analysts think the stock could climb as high as 107.78% to $29.36 over the next 12 months.
Life360 Inc (ASX: 360)
Life360 is a US-based software development company that took the tech industry by storm in 2025 before crashing by the end of the year. The company delivered a standout quarterly update in January, which beat expectations and caused a share price surge of nearly 30%. It looks like the business is poised for good growth this year, with some strong user acquisition numbers and monetisation expected by the end of the year. Data shows that 11 out of 14 analysts have a buy or strong buy rating on the ASX shares. The average target price is $43.03, which implies an 86.76% uplift over the next 12 months.
Lovisa Holdings Ltd (ASX: LOV)
The fashion jewellery and accessories retailer was hammered by a profit miss in its first-half FY26 results earlier this month, but some think the selling was overdone. The company's revenue figures were solid, though, and its sales growth remained positive. If it continues to grow in profitable markets, then its bottom line could be stronger than expected. Data shows the 16 analysts are split on their position for Lovisa shares. However, the average target price still represents a significant upside. I think the stock has legs to run further this year. Out of 16 analysts, 7 have a buy or strong buy, and another 8 have a hold rating. The average target price of $30.98 implies a 23.86% potential upside from the trading price at the time of writing.
CSL Ltd (ASX: CSL)
The ASX biotech share was the second-most traded stock among CommSec clients last week. The biotech stock has been subdued since it crashed 15% following its half-year results and shock CEO exit earlier this month. The latest downturn is just one of many headwinds the company has faced over the past 6 months. But I think the current share price offers investors an opportunity to buy the stock cheaply. There is still great growth potential and a strong core business. Analysts are mostly (12 out of 18) bullish, and the potential upsides are impressive. The average target price of $211.82 represents a possible 46.06% increase over the next 12 months, at the time of writing.
